Siddhartha P Kar

List of Publications by Year
in descending order

66 papers	4,537 citations	186265 28 h-index	123424 61 g-index
78 all docs	78 docs citations	78 times ranked	7398 citing authors

#	Article	IF	Citations
1	Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e467-e474.	3.6	13
2	Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis. Scientific Reports, 2022, 12, 1463.	3.3	4
3	Do sex hormones confound or mediate the effect of chronotype on breast and prostate cancer? A Mendelian randomization study. PLoS Genetics, 2022, 18, e1009887.	3.5	14
4	Selenium and cancer risk: Wide-angled Mendelian randomization analysis. International Journal of Cancer, 2022, 150, 1134-1140.	5.1	17
5	A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. Cell Reports Medicine, 2022, 3, 100542.	6.5	26
6	Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden. Journal of the National Cancer Institute, 2022, 114, 1159-1166.	6.3	8
7	chromMAGMA: regulatory element-centric interrogation of risk variants. Life Science Alliance, 2022, 5, e202201446.	2.8	1
8	Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nature Genetics, 2022, 54, 1155-1166.	21.4	109
9	Assessing the protective role of allergic disease in gastrointestinal tract cancers using Mendelian randomization analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1559-1562.	5.7	1
10	Genetically predicted circulating protein biomarkers and ovarian cancer risk. Gynecologic Oncology, 2021, 160, 506-513.	1.4	12
11	Sleep duration and risk of overall and 22 site-specific cancers: A Mendelian randomization study. International Journal of Cancer, 2021, 148, 914-920.	5.1	28
12	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. Cancer Research, 2021, 81, 1667-1680.	0.9	32
13	Genetically predicted circulating B vitamins in relation to digestive system cancers. British Journal of Cancer, 2021, 124, 1997-2003.	6.4	8
14	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
15	Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study. PLoS Medicine, 2021, 18, e1003706.	8.4	35
16	Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. Human Genetics and Genomics Advances, 2021, 2, 100041.	1.7	6
17	Assessing the role of cortisol in cancer: a wide-ranged Mendelian randomisation study. British Journal of Cancer, 2021, 125, 1025-1029.	6.4	17
18	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120

#	Article	IF	Citations
19	Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Medicine, 2020, 18, 327.	5.5	40
20	Genetically proxied milk consumption and risk of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian randomization study. BMC Medicine, 2020, 18, 370.	5.5	19
21	Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Medicine, 2020, 17, e1003178.	8.4	103
22	Insulinâ€like growth factorâ€1 and siteâ€specific cancers: A Mendelian randomization study. Cancer Medicine, 2020, 9, 6836-6842.	2.8	36
23	Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine, 2020, 59, 102956.	6.1	74
24	eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk Gene. American Journal of Human Genetics, 2020, 107, 778-787.	6.2	29
25	Is Type 2 Diabetes Causally Associated With Cancer Risk? Evidence From a Two-Sample Mendelian Randomization Study. Diabetes, 2020, 69, 1588-1596.	0.6	75
26	Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A twoâ€sample Mendelian randomization study. International Journal of Cancer, 2020, 147, 1895-1903.	5.1	45
27	Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study. Nutrients, 2020, 12, 526.	4.1	21
28	Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. ELife, 2020, 9, .	6.0	23
29	Title is missing!. , 2020, 17, e1003178.		0
30	Title is missing!. , 2020, 17, e1003178.		0
31	Title is missing!. , 2020, 17, e1003178.		0
32	Title is missing!. , 2020, 17, e1003178.		0
33	Title is missing!. , 2020, 17, e1003178.		0
34	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
35	A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants. Nature Genetics, 2019, 51, 815-823.	21.4	89
36	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecologic Oncology, 2019, 153, 343-355.	1.4	28

#	Article	IF	Citations
37	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. International Journal of Epidemiology, 2019, 48, 1727-1730.	1.9	3
38	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	5.7	16
39	Genetic predisposition to mosaic Y chromosome loss in blood. Nature, 2019, 575, 652-657.	27.8	198
40	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 395-404.	2.5	33
41	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
42	Addressing underlying causes of violence against doctors in India. Lancet, The, 2017, 389, 1979-1980.	13.7	21
43	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
44	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
45	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
46	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 2017, 8, 50930-50940.	1.8	43
47	Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
48	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
49	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
50	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
51	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast‐ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
52	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
53	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
54	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. PLoS ONE, 2016, 11, e0158984.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Germline polymorphisms in an enhancer of *PSIP1* are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	1.8	29
56	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
57	Network-Based Integration of GWAS and Gene Expression Identifies a *HOX*-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
58	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
59	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
60	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
61	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
62	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
63	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
64	Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Human Molecular Genetics, 2014, 23, 5294-5302.	2.9	71
65	Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Annals of Neurology, 2011, 70, 59-69.	5.3	259
66	Personalized therapy for pancreatic cancer: Myth or reality in 2010?. Journal of Gastrointestinal Oncology, 2010, 1, 24-33.	1.4	4